For the quarter ending 2025-09-30.
| Income Statement | 2025-09-30 | 2025-06-30 | ||
|---|---|---|---|---|
| Research and development | 2,589.749 | 1,730 | ||
| General and administrative | 1,503.326 | 1,504.295 | ||
| Total operating expenses | 4,093.074 | 3,234.295 | ||
| Loss from operations | -4,093.074 | -3,234.295 | ||
| Other income | 0 | - | ||
| Interest income | 655.473 | 780.769 | ||
| Net loss | -3,437.601 | -2,453.526 | ||
| Foreign currency translation gain (loss) | -0.116 | -3.456 | ||
| Unrealized gain (loss) on investments | -65.763 | 102.817 | ||
| Comprehensive loss | -3,503.48 | -2,354.165 | ||
| Basic EPS | -0.48 | -0.35 | ||
| Basic Average Shares | 7,123,849 | 6,998,000 | ||
Monopar Therapeutics (MNPR)
Monopar Therapeutics (MNPR)